Rucaparib provides promise for patients with high-grade ovarian cancer

A Phase I-II study supported by UCL ECMC has found that rucaparib can be used in the treatment of patients with high-grade ovarian cancer.

This study was the first to fully evaluate single-agent oral rucaparib, a PARP inhibitor, in patients with advanced solid tumors who had already undergone significant treatment for their cancer.

According to the results of an analysis, the majority of heavily pre-treated patients with high-grade ovarian cancer and germline or somatic BRCA1/2 mutations showed a durable response to rucaparib.

The promising results showed that 79% of patients remained progression-free after 6 months. At 12 months, that number was still over 40%, and at nearly 2 years, approximately 10% of women still had not progressed. This is exciting data, particularly for this heavily pre-treated, relatively platinum-sensitive patient population.